Summit Therapeutics Inc. (SMMT) Balance Sheet

The balance sheet has strengthened significantly over the past two years, primarily due to substantial equity raises, as evidenced by the jump in cash from $48.8M in 2024Q1 to $419.4M in 2026Q2. This influx of capital appears to be strategically timed to fund the escalating R&D expenses associated with the ivonescimab clinical program, which have surged to $157.7M in 2026Q2. However, the rapid increase in total liabilities from $105.6M to $122.2M over the same period, coupled with the negative retained earnings of -$2.7B, suggests that the balance sheet strength is heavily reliant on external financing rather than operational performance.

The reported leverage metrics appear conservative, with a D/E ratio of 0.03 and total debt of $20.4M, down from a peak of $87.3M in 2024Q1. This deleveraging suggests that the company has reduced its reliance on debt financing, likely through equity raises. However, the balance sheet does not capture the substantial future milestone obligations owed to Akeso under the licensing agreement, which could represent significant cash outflows if clinical and regulatory milestones are achieved. Investors should monitor the potential for future debt or equity issuance to fund these obligations, as the current cash position of $419.4M may not be sufficient to cover both ongoing R&D burn and milestone payments.

The asset composition is typical of a pre-revenue biotech, with cash comprising the majority of total assets and negligible investment in tangible fixed assets. Goodwill of $2.0M is immaterial, indicating that the company's value is derived from its intangible clinical assets, particularly the ivonescimab license. The low PPE of $21.2M suggests an asset-light model, with capital directed toward R&D rather than manufacturing infrastructure. This mix implies that the balance sheet's value is highly dependent on the success of the clinical pipeline, and any setback in the ivonescimab program could significantly impair the company's asset base.

The substantial increase in equity from $35.2M to $630.0M over the period is almost entirely attributable to equity issuances, as evidenced by the persistent and growing negative retained earnings. The company has not generated any profits, and the accumulated deficit has expanded from -$825.9M to -$2.7B, reflecting the heavy investment in R&D and stock-based compensation. The reliance on dilutive financing to fund operations suggests that existing shareholders face significant dilution risk, particularly as the company continues to burn cash at an accelerating rate. The quality of equity is therefore low, as it is not backed by retained earnings but by external capital injections.

The current ratio of 6.96 indicates a strong short-term liquidity position, with cash and equivalents of $419.4M providing a substantial buffer against near-term obligations. However, the company's operating cash burn has escalated to $168.7M in 2026Q2, implying that the current cash position may only sustain operations for about two to three quarters without additional financing. This suggests that while the balance sheet appears liquid, the company will likely need to access capital markets in the near future to fund its ongoing clinical trials and operational expenses. Investors should monitor the company's ability to raise additional funds, as any delay or unfavorable terms could strain liquidity.